Table 3.
Selection of current anti-LAG-3 (relatlimab) clinical trials. Information sourced from ClinicalTrials.gov.
| Trial | Aim | Target molecules | Condition | Phase |
|---|---|---|---|---|
| NCT02658981 | To evaluate the safety and most effective dose of relatlimab or urelumab (CD137) alone and in combination with nivolumab | Relatlimab: anti-LAG-3 mAb Urelumab: anti-CD137 mAb | Recurrent glioblastoma | I |
| NCT03335540 | Evaluate the treatment of solid tumors with various immunotherapy combinations (nivolumab, relatlimab, cabiralizumab, ipilimumab, anti-GITR, IDO1 inhibitor, lirilumab and radiation therapy | Nivolumab: anti-PD-1 mAb Relatimab: anti-LAG-3 mAb Cabiralizumab: anti-CTF1R mAb Ipilimumab: anti-CTLA mAb Lirilumab: anti-KIR mAb Anti-GITR IDO1 inhibitor | Broad biomarker assessment | I |
| NCT01968109 | To assess the safety, tolerability and efficacy of relatlimab alone and in combination with nivolumab in patients with unresectable/metastatic cancer | Nivolumab: anti-PD-1 mAb Relatlimab: anti-LAG-3 mAb | Not previously treated with immunotherapy: • NSCLC • Gastric cancer • Hepatocellular carcinoma • Renal cell carcinoma • Bladder cancer • Squamous cell carcinoma of the head and neck • Melanoma Previously treated with immunotherapy • NSCLC • Melanoma |
I/II |
| NCT02488759 | To investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy (relatlimab, ipilimumab and daratumumab) | Relatlimab: anti-LAG-3 mAb Ipilimumab: anti-CTLA mAb Daratumumab: anti-CD38 mAb | Virus associated cancers: • Anal canal cancer • Cervical cancer • Epstein Barr Virus (EBV) positive gastric cancer • HPV positive and negative squamous cell cancer of the head and neck (SCCHN) • Merkel Cell Cancer • Nasopharyngeal cancer (NPC) • Penile cancer • Vaginal and vulvar cancer |
I/II |
| NCT02061761 | To evaluate the safety, tolerability and maximum tolerated dose of relatlimab administered alone or in combination with nivolumab to subjects with relapsed hematologic malignancies | Nivolumab: anti-PD-1 mAb Relatimab: anti-LAG-3 mAb | • Relapsed or refractory Hodgkin lymphoma (HL), • Relapsed or refractory Diffuse Large B Cell lymphoma (DLBCL) |
I/II |
| NCT03459222 | To investigate safety and anti-tumor activity of relatlimab combination therapy in metastatic/unresectable solid cancers | Relatimab: anti-LAG-3 mAb | Incurable metastatic/unresectable solid tumor excluding CNS metastases | I/II |
| NCT02750514 | To evaluate the efficacy of nivolumab in combination with other agents (dasatinib, relatlimab, IDO1 inhibitor) | Nivolumab: anti-PD-1 mAb Relatimab: anti-LAG-3 mAb Dasatinib: tyrosine kinase inhibitor IDO1 inhibitor | NSCLC | II |
| NCT02996110 | To compare the efficacy and safety of nivolumab combination therapies (relatlimab/IDO1 inhibitor) with nivolumab and ipilimumab | Nivolumab: anti-PD-1 mAb Relatimab: anti-LAG-3 mAb Ipilimumab: anti-CTLA mAb IDO inhibitor | Renal cell carcinoma | II |
| NCT02935634 | To compare the efficacy and safety of nivolumab combination therapies (relatlimab/IDO1 inhibitor) with nivolumab and ipilimumab | Nivolumab: anti-PD-1 mAb Relatimab: anti-LAG-3 mAb Ipilimumab: anti-CTLA mAb IDO inhibitor | Gastric cancer | II |
| NCT03470922 | To compare the efficacy of nivolumab in combination with relatlimab and nivolumab alone | Nivolumab: anti-PD-1 mAb Relatimab: anti-LAG-3 mAb | Unresectable/metastatic melanoma | II/III |